NewEdge Advisors’s Denali Therapeutics DNLI Stock Holding History

NewEdge Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-400	Closed	-$7.68K	–	4242
2026 Q1	$7.68K	Hold	400	–	–	﹤0.01%	3466
2025 Q4	$6.6K	Hold	400	–	–	﹤0.01%	3594
2025 Q3	$5.81K	Hold	400	–	–	﹤0.01%	3486
2025 Q2	$5.6K	Hold	400	–	–	﹤0.01%	3380
2025 Q1	$5.44K	Buy	+400	New	+$7.66K	﹤0.01%	3281

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's DNLI Position: Q2 2026 in Review

NewEdge Advisors sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 400 shares — an estimated $7.68K sold.

NewEdge Advisors first reported a position in DNLI in Q1 2025 and held it in 5 quarters. The position peaked at $7.68K in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

NewEdge Advisors reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 400 Denali Therapeutics shares in Q2 2026, an estimated $7.68K.
NewEdge Advisors first reported a position in Denali Therapeutics in Q1 2025 and held it in 5 quarters.
NewEdge Advisors's Denali Therapeutics position peaked at $7.68K in Q1 2026.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.